ALNY
Alnylam Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
174.00
close · 2026-10-29
value
63
cheaper than peers63
quality
81
stronger fundamentals81
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
caveat margins at their own peak
Value inputs
| measure | company | vs peers |
| cash flow yield, latest year | 1.5% | 77 |
| price to sales | 4.85× | 75 |
| cash flow yield, 2 years ago | 0.1% | 68 |
| cash flow yield, 3 years ago | -2.0% | 68 |
| cash flow yield, 1 year ago | -0.1% | 68 |
| earnings yield, 1 year ago | -1.0% | 68 |
| earnings yield, 2 years ago | -1.5% | 68 |
| forward P/E | 14.09× | 63 |
| earnings yield, 3 years ago | -4.1% | 59 |
| earnings yield, latest year | 1.0% | 59 |
| EV to EBITDA | 29.18× | 36 |
| price to book | 17.19× | 12 |
12 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 96.6% | 98 |
| operating margin | 17.9% | 86 |
| revenue growth | 66.9% | 71 |
| debt to equity | 220.6% | 11 |
4 of 4 measures available
Facts
| market cap | $23B |
| free cash flow | $271.5M |
| employees | 2,500 |
| first trade | 2004-06-01 |
| next earnings | 2026-10-29 |
| fundamentals updated | 2026-10-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 2.33 | -2.18 | -3.52 | -9.30 |
| free cash flow | $465.4M | -$42.6M | $41.9M | -$613.3M |
| net income | $313.7M | -$278.2M | -$440.2M | -$1.13B |
| revenue | $3.71B | $2.25B | $1.83B | $1.04B |
| unusual items | -$44.8M | -$173.8M | -$107.9M | -$204.6M |